Zydus Lifesciences Shares Rise as FDA Inspection Concludes Without Observations

Zydus Lifesciences Ltd announced the successful completion of a US FDA surveillance inspection at its API manufacturing facility in Ambernath, Maharashtra. The inspection, conducted from February 10 to 14, 2025, concluded with no observations, signaling compliance with regulatory standards. This positive outcome follows the company's strong Q3FY25 performance, where it reported a 30% increase in net profit to ₹1,023 crore and a 17% rise in revenue to ₹5,269 crore. The news has boosted investor confidence, with Zydus Lifesciences shares trading up over 2% in early market hours.

 

Source: CNBC TV18, Moneycontrol, Samco